丽珠肠乐治疗肠易激综合征临床观察

应用丽珠肠乐治疗观察了３０例肠易激综合征病人,临床治疗取得较满意效果。     

丽珠肠乐治疗脾曲综合征

应用丽珠肠乐治疗脾曲综合征３０例,有效率７９．２％。     

丽珠肠乐治疗肠道菌群失调24例

应用丽珠肠乐治疗内、外科住院病人肠道菌群失调２４例,治愈率７９％,好转１２．５％,无效３．５％。总的有效率９６．５％。     

丽珠肠乐在小儿外科的应用

丽珠肠乐在小儿急性阑尾炎术后应用,以及用于肠套叠的肠道准备,都与抗生素效果一样。     

丽珠肠乐在肝脏疾病的应用

丽珠肠乐在肝脏疾病的应用山东省淄博市中心医院２５５０３６袁胜安,郝伯彦山东省淄博第二卫生学校张东海蚌埠市卫生防疫站郭符则作者参阅了２２篇关于丽珠肠乐在肝脏疾病方面应用的论文,进行了讨论。内容涉及肝炎、肝硬化、肝性脑病、免疫、发病机理、内毒素等多方面的...     

丽珠肠乐治疗小儿冠状病毒肠炎32例疗效观察

丽珠肠乐治疗轮状病毒肠炎多有报导,但丽珠肠乐治疗冠状病毒肠炎却罕见。我科在１９９６年１０月－１２月对３２例住院冠状病毒肠炎患儿给予口服双歧杆菌活菌制剂（由珠海丽珠医药集团股份有限公司生产的丽珠肠乐）治疗,并与口服庆大霉素组３０例进行对照,观察丽珠肠乐的疗效,现作小结。     

丽珠肠乐治疗婴幼儿秋季腹泻40例疗效分析

秋季腹泻是婴幼儿秋季季节的常见病,本文６８例病人随机分为２组,治疗组４０例,对照组２８例,治疗组应用丽珠肠乐对照组应用氟哌酸或氨苄青霉素,其它治疗相同。结果表明：治疗组在止泻时间、退热时间、脱水纠正时间、病程等方面均较对照组为短,统计学处理差别具有显著性,说明丽珠肠乐治疗婴幼儿秋季膜泻其效果显著。     

丽株肠乐治疗慢性腹泻15例

应用丽珠肠乐治疗肝硬化腹泻肝癌腹泻及其它慢性腹泻共１５例,有效率９３％。     

微生态制剂(贝飞达)治疗非便秘型肠易激综合征

目的探讨微生态制剂贝飞达对肠易激综合征（IBS）的疗效。方法采用中国预防医学科学院流行病学研究所海斯药业有限公司生产的双歧三联活菌胶囊贝飞达（长双歧杆菌、嗜酸乳酸杆菌、粪肠球菌）治疗25例IBS患者,与服用安慰剂组25例进行疗效对比分析。结果IBS特征性症状评分治疗前后的差值,治疗组明显高于安慰剂组,各种症状的改善率明显优于对照组。结论贝飞达的短期疗法有望成为IBS治疗中的一个颇有前途的手段。     

益生菌联合复方谷氨酰胺治疗腹泻型肠易激综合征的临床疗效分析

目的 益生菌联合复方谷氨酰胺治疗腹泻型肠易激综合征(IBSD)的临床疗效及其对胃动素(MOT)、血管活性肠肽(VIP)和生长抑素(SS)水平的影响。 方法 选取我院2018年1月至2019年12月期间门诊及住院部收治的IBSD患者66名,随机分为2组。两组患者入组后均进行健康饮食宣教、心理评估等。A组患者采用复方谷氨酰胺肠溶胶囊治疗,B组在A组基础上加用双歧杆菌三联活菌胶囊治疗。比较两组患者临床有效率、汉密尔顿焦虑量表(HAMA)评分、汉密尔顿抑郁量表(HAMD)评分、肠易激综合征症状严重程度量表(IBSSSS)评分及MOT、VIP和SS水平。 结果 B组疗效显著好于A组,差异有统计学意义(P0.05)。 结论 双歧杆菌三联活菌联合复方谷氨酰胺显著改善了IBSD患者的临床症状,提高了外周血MOT水平,降低了VIP和SS水平,临床疗效满意,可在IBSD中推广应用。     

阿洛司琼联合微生态制剂治疗腹泻型肠易激综合征的临床研究

目的:探究阿洛司琼联合微生态制剂治疗腹泻型肠易激综合征的临床效果。方法:选择2016年1月-2018年1月于我院进行治疗的96例腹泻型肠易激综合征患者为研究对象,按照随机数字表法将其均分为实验组与对照组,每组各48例。对照组患者单纯使用阿洛司琼治疗,实验组患者在对照组患者基础上加用微生态制剂,两组患者治疗时间均为4周,分别于干预前及干预后对两组患者症状进行评分,使用IBS病情严重程度调查表(IBS-SSS)对两组患者干预前后治疗效果进行评估,并比较两组患者干预前后肠道乳酸杆菌、肠球菌及酵母样真菌菌群数及生活质量(SF-36)评分。结果:干预后,实验组患者症状评分及IBS-SSS量表评分均显著低于对照组(P0.05),SF-36生理功能、心理功能及生活功能得分、乳酸菌及肠球菌菌群数均显著高于对照组,而酵母样真菌菌群数低于对照组(P0.05)。结论:阿洛司琼联合微生态制剂治疗腹泻型肠易激综合征能够有效改善患者的肠道菌群、有效缓解临床症状,并可显著提高患者的生活质量。     

肠道菌群与腹泻型肠易激综合征相关性的研究进展

肠易激综合征（IBS）是一种常见的功能性胃肠道疾病,其特征是反复发作的腹痛,伴随排便频率与大便性状的改变。腹泻为主的肠易激综合征（IBS-D）是其主要亚型,主要表现是腹痛和腹泻。目前IBS-D的发病机制尚不完全明确,但大量的研究提示可能与胃肠道动力紊乱、黏膜通透性和肠上皮屏障功能改变、内脏高敏感性增加、“脑‒肠‒菌”轴失调、肠道感染与炎症反应激活、精神心理因素异常等有关。随着研究的不断深入,发现肠道菌群与IBS-D的关系密切,调节肠道菌群的益生菌干预成为缓解IBS-D相关症状的手段之一。本研究就近十余年来肠道菌群情况与IBS-D关系的研究现状作一综述。     

布拉酵母联合奥替溴铵对腹泻型肠易激综合征的疗效

目的 探讨布拉酵母联合奥替溴铵对腹泻型肠易激综合征（IBS-D）的临床疗效。方法 将80例IBS-D患者随机分为对照组和观察组各40例。对照组患者采用奥替溴铵40 mg/次,3次/d,口服。观察组患者在对照组基础上联用布拉酵母0.5 g/次,2次/d,饭前30 min口服。4周为一疗程。结果 治疗后观察组患者腹泻症状消失时间和用药总时间明显短于对照组（P＜0.05）。观察组患者临床总有效率（95.0%）高于对照组（67.5%）,两组比较差异有统计学意义（P＜0.01）。观察组患者治疗后抑郁与焦虑评分明显低于对照组,差异有统计学意义（P＜0.01）。结论 布拉酵母联合奥替溴铵对IBS-D患者临床疗效明显,可以迅速控制患者腹泻症状,减少患者用药不良反应。     

Yogic Versus Conventional Treatment in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Control Study

This study was conducted to evaluate the comparative effect of yogic and conventional treatment in diarrhea-predominant irritable bowel syndrome (IBS) in a randomized control design. The patients were 22 males, aged 20-50 years, with confirmed diagnosis of diarrhea-predominant IBS. The conventional group (n = 12, 1 dropout) was given symptomatic treatment with loperamide 2-6 mg/day for 2 months, and the yogic intervention group (n = 9) consisted of a set of 12 asanas (yogic poses, i.e., Vajrasana, Shashankasana, Ushtrasana, Marjariasana, Padhastasana, Dhanurasana, Trikonasana in two variations, Pawanmuktasana, and Paschimottanasana) along with Surya Nadi pranayama (right-nostril breathing) two times a day for 2 months. All participants were tested at three regular intervals, at the start of study--0 month, 1 month, and 2 months of receiving the intervention--and were investigated for bowel symptoms, autonomic symptoms, autonomic reactivity (battery of five standard tests), surface electrogastrography, anxiety profile by Spielberger's Self Evaluation Questionnaire, which evaluated trait and state anxiety. Two months of both conventional and yogic intervention showed a significant decrease of bowel symptoms and state anxiety. This was accompanied by an increase in electrophysiologically recorded gastric activity in the conventional intervention group and enhanced parasympathetic reactivity, as measured by heart rate parameters, in yogic intervention group. The study indicates a beneficial effect of yogic intervention over conventional treatment in diarrhea-predominant IBS.     

Comparison of Treatment Outcome Measures for Irritable Bowel Syndrome

We have examined the relations among three common treatment outcome measures in irritable bowel syndrome (IBS): end of treatment global ratings by a physician, end of treatment patient global ratings, and measures derived from a daily symptom diary completed by the patient. Eighty-four IBS patients (53 female, 31 male) participated in a randomized controlled evaluation of three psychological treatment conditions for IBS. Treatment outcome measures from this trial (Blanchard et al., 1992) were used in the present methodological study. Physician global ratings were significantly correlated with patient global ratings (r = .45, p < .01). Both of these global ratings also correlated significantly with a composite score from patient diary ratings. Multiple regression analyses revealed that reductions in bloating and constipation account for 18% of the variance in patient global ratings. Global ratings at end of treatment by either patient or physician were only partially related to symptom relief as measured by a daily diary.     

The influence of the two different light intensities duringthe daytime on the colon motility in patients with irritable bowel syndrome (IBS): a preliminary report

Irritable bowel syndrome (IBS) is the most frequent functional disorder of the gastrointestinal tract, with great economical impact. The etiology and pathogenesis of the disease are unclear. Among patients seeking medical attention for IBS, 70 - 90% have psychiatric co-morbidity, most commonly major depression. In this study we test the influence of bright light on colon motility and subjectively felt symptoms. Eight IBS patients participated in the experiment. The passage rate was evaluated twice for every person: (1) after three days of exposure to bright light -3000 lux (from 8:00 to 18:00), (2) after three days exposure to dim light -100 lux (from 8:00 to 18:00). The comparison of colonic time in IBS patients point to differences in the elimination of markers, depending on experimental light conditions. After bright light conditions a tendency is observed to slower elimination of markers in the IBS-diarrhoea patients, and to a quicker elimination in the IBS-constipated patients. According to subjective feeling, all IBS patients reported an improvement in bowel function and relief of pain after bright but not after dim light application. Results of this preliminary study suggest that phototherapy might be a valuable addition to the conventional treatment of IBS.